Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys Unit to Use Thermo Fisher's Fluorescent Dyes to Develop Reagents

NEW YORK (GenomeWeb News) — Thermo Fisher Scientific today said synthetic antibody developer AbD Serotec will use its DyLight dyes as part of a collaborative agreement to develop a series of fluorescent reagents.
 
Under the agreement, Serotec, a subsidiary of MorphoSys, will develop and sell the resulting products through its catalog, Thermo said.
 
Thermo said its DyLight products are water soluble and provide high fluorescent intensity in various applications.
 
Serotec has a catalog of more than 10,000 research antibodies, and it develops monoclonal antibodies using its parent company’s HuCal technology.
 
Financial terms of the agreement were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.